FGFR2 single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
FGFR2
Disease:
Prostate cancer, cholangiocarcinoma, epidermal nevus, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, colon adenocarcinoma, lung adenocarcinoma, gastric carcinoma, ovarian, cervical, pancreatic, head and neck cancers. Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis.
Molecular test that utilizes NGS technology to detect mutations in FGFR2. A gene that makes a protein that is involved in cell division, cell maturation, formation of new blood vessels, wound healing, and bone growth and development. A mutation (change) in the FGFR2 gene may cause the FGFR2 protein to become overactive in certain bone disorders, genetic conditions, and cancers. Also called fibroblast growth factor receptor 2 gene.
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of each DNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 1.7-1.9 and 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored DNA or RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic DNA must be stored at 2–8°C for several weeks post extraction, then at –15 to –25°C for long term storage
CPT(s)
81479 or 81404
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
